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The heterogeneity of cancer stem-like 
cells at the invasive front
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Abstract 
Cancer stem-like cells exhibit the multi-functional roles to survive and persist for a long period in the minimal residual 
disease after the conventional anti-cancer treatments. Cancer stem-like cells of solid malignant tumors which highly 
express CD44v8-10, the variant isoform of CD44 generated by alternative splicing, has a resistance to redox stress by 
the robust production of glutathione mediated by ESRP1-CD44v-xCT (cystine/glutamate antiporter) axis. It has been 
reported that CD44v and c-Myc tend to show the inversed expression pattern at the invasive front of the aggres-
sive tumors. Given that the accumulation of reactive oxygen species triggers the activation of Wnt/β-catenin signal 
pathway, it is hypothesized that CD44v causes the negative feedback machinery in the regulation of c-Myc expression 
via the attenuated ROS-induced Wnt signal pathway. To address the fundamental question whether and how both 
proliferative and quiescent cancer stem-like cells heterogeneously exist at the invasive/metastatic edge, researchers 
need to investigate into the E3-ubiquitin ligase activity essential for c-Myc degradation. CSCs heterogeneity at the 
invasive/metastatic front is expected to demonstrate the dynamic tumor evolution with the selective pressure of 
anti-cancer treatments. Furthermore, the novel molecular targeting therapeutic strategies would be established to 
disrupt the finely-regulated c-Myc expression in the heterogeneous CSC population in combination with the typical 
drug-repositioning with xCT inhibitor.
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Background
Metastatic and relapsed diseases account for more than 
90% of cancer deaths. Minimal residual disease (MRD), 
which is undetectable in the clinical settings, is widely 
accepted to be responsible for the latent relapse and dis-
tant metastasis. The heterogeneous tumor cell population 
undergoes the selective pressure such as hypoxia, hypo-
nutrient conditions, chronic inflammation, and activated 
innate immune system. The selective pressure of the 
unfavorable tumor microenvironment is considered to 
transiently decrease the degree of the intra-tumoral het-
erogeneity, which is referred to as “bottle-neck effect” in 
the evolutionary theory [1].
Cancer stem-like cells (CSCs) are defined as the 
enhanced tumorigenic subpopulation of cancer cells. 
They exist at the top of the hierarchical tumor cell soci-
ety composed of CSCs, transit-amplifying cells, and 
non-CSCs. CSCs exhibit self-renewal potential and can 
generate numerous progenitor/daughter cells at various 
degrees of differentiation in much the same way as nor-
mal tissue stem cells. Accumulating evidence has strongly 
suggested that CSCs can persist after currently avail-
able anti-cancer medical interventions such as chemo-
therapy and radiotherapy. Several molecular machineries 
underlying this therapeutic resistance specific to CSCs 
have been identified, including the resistance to oxida-
tive stress and chronic inflammation, the maintenance 
of quiescent status of the cell cycle, a rapid response to 
DNA damage, and the robust export of cytotoxic agents. 
Therefore, MRD is enriched in CSCs with high tumori-
genic potential and chemo-resistance [2].
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Conventional anti-cancer therapies preferentially kill 
the proliferative non CSCs and proliferative CSCs, which 
is explains the reason why quiescent CSCs tend to persist 
in MRD for a long period. Residual dormant CSCs which 
have survived after the anti-cancer treatment are responsi-
ble for the tumor relapse and distant metastasis after their 
re-entry into the cell cycle. Remarkably, a recent investi-
gation reveals that prostaglandin E2 (PGE2), the cytokine 
involved in the chronic inflammation and wound heal-
ing, is responsible for the iatrogenic activation of CSCs 
and the progressive development of chemo-resistance. 
Cytokeratin14-positive undifferentiated bladder CSCs in 
the dormant cell cycle G0 phase were induced to prolifer-
ate and repopulate the MRD on exposure to PGE2 which 
was released from non-CSC cells undergoing caspase-
dependent apoptosis due to the chemotherapy regimens 
characterized by gemcitabine and cisplatin. PGE2-medi-
ated canonical Wnt signal activation in dormant CSCs 
was responsible for c-Myc up-regulation and re-entry 
into the cell cycle [3, 4]. Taken together, the iatrogenic 
expansion of CSC population is highly likely to ironically 
cause the “chemotherapy-induced awakening” of dormant 
CSCs located in MRD with the up-regulation of “wound-
response gene signature” in the gene set enrichment anal-
ysis (GSEA), which is consistent with the conventional 
concept of “Cancers as wounds that do not heal [5].”
Wnt signal pathways are mainly classified into 
β-catenin–dependent canonical pathway and non-
canonical pathways. β-catenin plays fundamental roles 
both in the cell–cell adhesion and in the signal trans-
duction. Whereas β-catenin acts in collaboration with 
E-cadherin forming adherens junction between epithelial 
cells, β-catenin dissociated from adaptor protein complex 
composed of adenomatous polyposis coli (APC), Axin, 
and glycogen synthase kinase 3-β (GSK3-β) can enter the 
nucleus and function as a transcriptional factor in associ-
ation with T cell factor/lymphoid enhancer factor (TCF/
LEF). β-catenin phosphorylated by GSK3-β undergoes 
ubiquitin-proteasome-dependent protein degradation 
[6]. The expression level of c-Myc is finely regulated by 
both β-catenin-mediated transcription and E3-ubiqui-
tin-ligase (F-box and WD repeat domain-containing 7; 
Fbw7)-mediated post-translational degradation [7].
CD44 is one of the CSC markers of various kinds of 
solid tumors. CD44 is mainly classified into standard and 
variant isoforms, without or with variable exons, respec-
tively. CD44 standard isoform, which is predominantly 
expressed in mesenchymal cells, is known to interact 
with extracellular matrix such as hyaluronic acids. There 
are several forms of CD44 variant isoforms depending on 
which variable exons are inserted during the process of 
the alternative splicing [8]. In particular, CD44 variant 
8-10 (CD44v) prevents the accumulation of intracellular 
reactive oxygen species (ROS) by the stabilization of cys-
tine/glutamate antiporter at the cellular membrane, and 
subsequently, this CD44v-xCT axis promotes the synthe-
sis of the reduced from of glutathione (GSH) [9]. Given 
that epithelial splicing regulatory factor 1 (ESRP1) con-
tributes to the alterative splicing to specifically generate 
CD44v with variable exons 8-10, ESRP1-CD44v-xCT 
axis is recognized to regulate the redox balance in CSCs. 
Indeed, ESRP1-CD44v-xCT axis has been demonstrated 
to enhance the efficiency of breast cancer cells to form 
metastatic foci in the lungs; CD44v-positive 4T1 murine 
breast cancer cells are significantly able to metastasize 
to the lungs as compared with CD44v-negative 4T1 cells 
[10]. Collectively, ESRP1-CD44v-xCT axis efficiently reg-
ulates ROS level in CSCs.
CD44 and c-Myc are target molecules regulated 
by Wnt/β-catenin signal transduction. It is paradoxi-
cal, however, that CD44v and c-Myc tend to show the 
inversed correlation both in vitro experiments using gas-
tric cancer cell lines and in vivo analyses such as immune-
histochemical observations of the xenograft models and 
human tumor specimens [11]. The detailed molecular 
machinery underlying the relationship between CD44 
and c-Myc remains to be elucidated.
Presentation of the hypothesis
Mounting evidence has suggested that CSCs are enriched 
in the heterogeneous manner especially at the inva-
sive/metastatic front of the aggressive tumor. Cancer 
cells at the invasive area are expected to be composed 
of both quiescent CSCs exhibiting the expression pat-
tern of CD44v8-10 (high)/Fbw7 (high)/c-Myc (low) and 
proliferative CSCs exhibiting CD44v8-10 (high)/Fbw7 
(low)/c-Myc (high). The major reason why CD44v8-10 
and c-Myc tend to show the inversed expression pat-
tern is considered to be due to the negative feedback 
machinery towards ROS-induced canonical Wnt path-
way by CD44v expression (Fig.  1). ESRP1-CD44v-xCT 
axis has been shown to reduce intracellular ROS level 
and no longer activates the transcriptional level of c-Myc 
[11]. Surely, c-Myc is an oncogenic transcriptional fac-
tor regulated by not only ROS-induced Wnt/β-catenin 
signaling but also E-3-ubiquitin-ligase Fbw7. It is still yet 
to be demonstrated that Fbw7 contributes to the regula-
tion of c-Myc expression to induce heterogeneous CSCs 
at the invasive/metastatic lesion. It is possible that the 
heterogeneity of c-Myc stability largely depends on each 
CSC. Collectively, it is hypothesized that both negative-
feedback machinery due to ROS-induced canonical Wnt 
signal pathway and Fbw7-mediated degradation of onco-
genic transcription factor c-Myc are responsible for the 
heterogeneous distribution of CSCs enriched at the inva-
sive/metastatic foci.
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Testing the hypothesis
To address this hypothesis, it should be noted that both 
CD44 and c-Myc are regulated by Wnt/β-catenin signal 
pathway and those molecules are crucial for the mainte-
nance of CSC phenotype at the niche. Increased amount 
of Wnt ligands promotes c-Myc transcription and accel-
erates the cell cycle re-entry of G0/G1-phased dormant 
CSCs [2, 12]. CD44 has a longer half-life period than 
c-Myc, one of the oncogenic transcription factors [13]. 
When Wnt/β-catenin signal pathway is activated due to 
the increased ROS level, both CD44 and c-Myc are up-
regulated at the transcriptional level. However, given 
the difference in the stabilization as a molecule, c-Myc 
is expected to be soon down-regulated in CSCs highly 
expressing CD44v. By striking contrast, CD44 continues 
to reduce intracellular ROS level by promoting the GSH 
generation, resulting in the negative feedback machin-
ery of Wnt/β-catenin signaling transduction. On the 
other hand, there is the heterogeneity in terms of the 
expression level of c-Myc, which influences on the pro-
liferative potential of each CSC with abundant expres-
sion of CD44v. This heterogeneity of c-Myc expression 
occurs because of the heterogeneous degradation by 
the ubiquitin-proteasome cascade mainly regulated by 
Fbw7. So far, it remains to be elusive which Fbw7 iso-
form mainly contributes to the c-Myc regulation at the 
invasive/metastatic front. Alternative splicing generates 
three different protein isoforms of Fbw7 composed of 
Fbw7α, Fbw7β, and Fbw7γ. Their distribution determines 
depending on 5′ exon signals that direct the isoforms to 
distinct subcellular compartments; Fbw7α is nucleo-
plasmic, Fbw7β is cytoplasmic, and Fbw7γ is nucleolar, 
respectively. Furthermore, there are no reliable antibod-
ies available for Fbw7. Importantly, it would be difficult 
to identify the heterogeneity of CSC population at the 
invasive front derived from the biopsy or surgical speci-
men. CSCs are critically influenced by the microenvi-
ronment, which is why the complexity of heterogeneous 
CSCs at the invasive/metastatic lesion would exhibit the 
discrepancy as compared with the bona fide behavior of 
invasive CSC population.
Implications of the hypothesis
ROS is a double-edged sword for cancer cells. While the 
excessive level of ROS can induce apoptotic or necrotic 
cell death, the appropriate range of ROS level triggers 
cellular proliferation by influencing on several survival 
signal transductions characterized by canonical Wnt/β-
catenin pathway. Upon exposure to redox stress, nucle-
oredoxin (NRX) associated with redox-sensitive Wnt 
adaptor protein inhibits the ubiquitin ligase activity of 





























Fig. 1 Negative-feedback mechanism of ROS-induced Wnt/β-catenin signal in cancer stem-like cells. The exposure to oxidative stress activates Wnt 
pathway and up-regulates both CD44 and c-Myc (blue cells). CD44v8-10 stabilizes xCT (cystine/glutamate antiporter) and provides CSCs cystine, 
the rate-limiting substrate of glutathione synthesis. The decreased ROS level due to CD44v-xCT axis influences on ROS-induced Wnt signal in a 
negative-feedback manner (red cells). Both blue and red cells belong to CSCs, but c-Myc expression level is different each other, which makes the 
invasive CSCs population quite heterogeneous in terms of cell cycle and proliferation. Although the precise molecular machineries regulated by 
Fbw7 remain to be unknown, CD44v8-10 and c-Myc tend to exhibit the inversed expression pattern at the invasive front where heterogeneous 
CSCs are enriched
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spared from phosphorylation by GSK3β translocates 
into the nucleus and binds to TCF/LEF promoter, 
thereby enhancing the transcription of Axin-2, CD44, c-
Myc, CCND1, and β-catenin itself [14]. Thus, ROS can 
be either beneficial or harmful for cancer cells in the 
microenvironment.
Furthermore, the detailed molecular mechanism 
underlying the inversed expression pattern between CSC 
marker CD44v and oncogenic transcription factor c-Myc 
should be elucidated to better understand how aggres-
sively invasive/metastatic CSCs simultaneously regulate 
cell cycle and ROS level. c-Myc drives the cellular prolif-
eration and causes metabolic reprogramming of tumor 
cells. It has already been shown that Ki-67, the prolif-
erative marker, exhibits the reversed expression pattern 
as compared with CD44v [11]. From the perspective of 
tumor metabolism, c-Myc has been revealed to stimu-
late the expression of both Na+-dependent amino acid 
transporter ASCT2 and glutaminases (GLS) which is an 
essential enzyme for glutaminolysis. c-Myc promotes 
glutamine uptake via ASCT2 transporter and glutamine 
catabolism mediated by GLS mainly in the mitochondria. 
This excessive dependency on glutamine catabolism in 
cancer cells is referred to as “glutamine addiction [15] ”. 
It is likely that heterogeneous CSC population com-
posed of dormant CSCs with CD44v8-10 (high)/Fbw7 
(high)/c-Myc (low) and proliferative CSCs with CD44v8-
10 (high)/Fbw7 (low)/c-Myc (high) exhibit the metabolic 
symbiosis at the invasive/metastatic front.
While CD44v brings about the negative feedback loop 
against ROS-induced canonical Wnt signal activation, 
c-Myc would be easily down-regulated as compared with 
CD44 in terms of the difference in the half-life period. 
That is why CD44, especially CD44v8-10, and c-Myc tend 
to show the inversed expression pattern each other. In 
addition, the heterogeneous amount and activity of Fbw7 
ubiquitin ligase makes the heterogeneity of oncogenic 
c-Myc expression. This heterogeneous c-Myc expression 
at the invasive/metastatic lesion represents the diversity 
in the proliferative capacity of CSC population with robust 
CD44v expression. When researchers demonstrate the 
regulation machinery underlying the heterogeneous CSCs 
at the invasive/metastatic edge, the therapeutic strategy 
against tumor invasion and metastasis by targeting CSCs 
would be much more validated. As mentioned above [3], 
the chemotherapy can stimulate dormant CSCs and induce 
the therapeutic resistance to the conventionally effective 
drugs. Collectively, the heterogeneous CSCs at the inva-
sive/metastatic edge is expected to reveal the dynamic evo-
lution with the selective pressure of anti-cancer treatments.
Last but certainly not least, the novel molecular tar-
geting therapies against aggressive CSCs would be more 
warranted. Sulfasalazine, the conventional drug for the 
treatment of rheumatoid arthritis and ulcerative colitis, 
has been revealed to inhibit the function of xCT trans-
porter [9, 10]. This is the typical example of the drug 
re-positioning, finding out the novel anti-tumor effect 
of conventionally used agents. As compared with novel 
molecular-targeting drugs, conventionally-used agents 
are pharmacologically safe and beneficial for medical 
economy. Indeed, sulfasalazine has been shown to reduce 
the proliferation of CD44v-highly expressing cancer cells 
in the clinical trials on advanced gastric and pulmonary 
tumors [2, 15]. CSCs enriched at the invasive/metastatic 
front with enhanced level of ROS are likely to disappear, 
when ERSP1-CD44v-xCT axis is disrupted by sulfasala-
zine treatment. Given that c-Myc drives the cell division 
and promotes the glutamine metabolism [15], the molec-
ular targeting drug for this oncogenic transcriptional fac-
tor would show the synergistic therapeutic effect against 
CSCs at the invasive/metastatic front with xCT inhibitor.
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